Teva, mAbxience expand partnership for additional oncology biosimilar candidate
Teva and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, announced a new global licensing agreement for the development of an anti PD-1 oncology biosimilar candidate. This marks the second agreement between the two companies, reinforcing the solid foundation of the collaborative efforts that commenced in April 2024.
mAbxience will lead the development and production of the biosimilar, utilizing its state-of-the-art, cGMP-compliant facilities in Spain and Argentina, while Teva will manage regulatory approvals and oversee commercialization in the designated markets.
The global agreement to develop an additional oncology biosimilar further strengthens the alliance between Teva and mAbxience, underscoring the shared goal to provide cost-effective, high-quality biosimilar treatments that address critical unmet needs in oncology care. By leveraging each company’s unique expertise and resources, the collaboration continues to drive innovation and accessibility in health care to create solutions for patients worldwide.
[Read more: AAM, Biosimilars Council releases statement on statement on Senate Judiciary Markup of PREVAIL and PERA]
The licensing agreement includes exclusive rights for multiple markets, including Europe and the United States, and aligns with mAbxience's strategy for global expansion. The collaboration reflects Teva's progress advancing its Pivot to Growth strategy by adding a new biosimilar to the company’s broad portfolio of biosimilars, through focused partnerships and business development efforts.
Similar to the initial contract, under the terms of this agreement, mAbxience will lead the development and production of the biosimilar, utilizing its state-of-the-art, cGMP-compliant facilities in Spain and Argentina. Teva will manage regulatory approvals and oversee commercialization in the designated markets, ensuring that patients around the world gain access to this oncology treatment.
Angus Grant, executive vice president of business development at Teva, said, “We are excited to deepen our collaboration with mAbxience. This agreement not only strengthens our alliance but also highlights our shared dedication to expanding access to critical oncology treatments. This collaboration with mAbxience reflects Teva’s ideal strategic partnership model to optimize development costs, apply our regulatory expertise and leverage our extensive commercial capabilities to bring new treatment options to people living with serious medical conditions.”
[Read more: Prioritizing Lower-Priced Biosimilar Medications]
“Building on our first agreement with Teva signed earlier this year, this second collaboration is a testament to the strength of our partnership and the shared vision of both companies,” said Jurgen Van Broeck, CEO of mAbxience. “This agreement reinforces our commitment to making high-quality biosimilars accessible and improving healthcare outcomes on a global scale.”